Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,580
  • Shares Outstanding, K 74,370
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,020 K
  • 36-Month Beta 1.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.23
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.41 +3.55%
on 12/11/18
1.92 -23.96%
on 11/28/18
-0.19 (-11.52%)
since 11/13/18
3-Month
1.41 +3.55%
on 12/11/18
1.99 -26.63%
on 09/20/18
-0.36 (-19.78%)
since 09/13/18
52-Week
1.41 +3.55%
on 12/11/18
4.09 -64.30%
on 12/27/17
-1.69 (-53.65%)
since 12/13/17

Most Recent Stories

More News
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib

- 44% of transfusion dependent myelofibrosis patients (multi-study aggregate N=152) were transfusion free for at least 12 weeks; 49% were transfusion free for at least 8 weeks - - Data from translational...

SRRA : 1.46 (-7.01%)
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737

SRA737 synergizes with immune checkpoint blockade in small cell lung cancer (SCLC) - - Activates immune signaling STING pathway - - Data reported at the AACR Conference on Tumor Immunology and Immunotherapy...

SRRA : 1.46 (-7.01%)
Sierra Oncology to Host Analyst Call Highlighting Clinical Data on Momelotinib's Anemia Benefit

Call to include Dr. Srdan Verstovsek and will discuss emerging clinical data demonstrating momelotinib's unique anemia benefit in patients with myelofibrosis -

SRRA : 1.46 (-7.01%)
Sierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR Symposium

SRA737 demonstrates preclinical efficacy in aggressive CCNE1-amplified and MYCN--overexpressing high-grade serous ovarian cancer patient-derived xenograft (PDX) models -- PDX models were refractory to...

SRRA : 1.46 (-7.01%)
Sierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR Symposium

Novel oral Cdc7 inhibitor, SRA141, demonstrates competitive target selectivity and robust efficacy in several cancer models -

SRRA : 1.46 (-7.01%)
Sierra Oncology Reports Third Quarter Results

Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 Monotherapy and LDG Combination trial preliminary data anticipated in H1 2019 -

SRRA : 1.46 (-7.01%)
Sierra Oncology to Present at the Jefferies 2018 London Healthcare Conference

- "Targeted Therapeutics for Hematology & Oncology" scheduled for 5:20 p.m. GMT on November 14, 2018 -

SRRA : 1.46 (-7.01%)
Sierra Oncology to Report Clinical Data at ASH 2018 from Translational Biology Study of Momelotinib in Transfusion Dependent Patients

Biomarker data obtained from 41 transfusion dependent patients support ACVR1 mechanism of action for momelotinib's anemia benefit in myelofibrosis -

SRRA : 1.46 (-7.01%)
Sierra Oncology to Host KOL Call with Dr. Srdan Verstovsek Presenting "Unmet Medical Needs in Myelofibrosis"

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology,...

SRRA : 1.46 (-7.01%)
Sierra Oncology Reports First Quarter Results

SRA737 Monotherapy Phase 1/2 trial expanded to enroll CCNE1-driven ovarian cancer cohort - - SRA737 Low-Dose Gemcitabine Combination Phase 1/2 trial advanced into cohort expansion phase - - $133.8 million...

SRRA : 1.46 (-7.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade SRRA with:

Business Summary

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central...

See More

Key Turning Points

2nd Resistance Point 1.63
1st Resistance Point 1.55
Last Price 1.46
1st Support Level 1.41
2nd Support Level 1.36

See More

52-Week High 4.09
Fibonacci 61.8% 3.07
Fibonacci 50% 2.75
Fibonacci 38.2% 2.43
Last Price 1.46
52-Week Low 1.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar